Published in Oncology Business Week, December 18th, 2005
Abraxane is being commercialized in North America by Abraxis Oncology, a division of American Pharmaceutical Partners, Inc., (APPX).
Annual taxane sales in Japan are growing with the Japanese market for chemotherapy agents being approximately $3 billion. Taiho, which is based in Tokyo, is part of Otsuka Pharmaceutical, Ltd., one of the largest pharmaceutical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week